DK1292303T3 - Stabil farmaceutisk formulering omfattende torsemidmodifikation II - Google Patents

Stabil farmaceutisk formulering omfattende torsemidmodifikation II

Info

Publication number
DK1292303T3
DK1292303T3 DK01911078T DK01911078T DK1292303T3 DK 1292303 T3 DK1292303 T3 DK 1292303T3 DK 01911078 T DK01911078 T DK 01911078T DK 01911078 T DK01911078 T DK 01911078T DK 1292303 T3 DK1292303 T3 DK 1292303T3
Authority
DK
Denmark
Prior art keywords
torsemide modification
stable pharmaceutical
high purity
pharmaceutical formulation
modification
Prior art date
Application number
DK01911078T
Other languages
Danish (da)
English (en)
Inventor
Minutza Leibovici
Ruth Tenengauzer
Mira Kopel
Judith Aronhime
Marco Kordova
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27359046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1292303(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK1292303T3 publication Critical patent/DK1292303T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01911078T 2000-02-17 2001-02-21 Stabil farmaceutisk formulering omfattende torsemidmodifikation II DK1292303T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18328800P 2000-02-17 2000-02-17
US09/789,424 US6482417B2 (en) 2000-02-17 2001-02-21 Stable pharmaceutical formulation comprising torsemide modification II
PCT/US2001/005577 WO2002067935A1 (en) 2000-02-17 2001-02-21 A stable pharmaceutical formulation comprising torsemide modification ii

Publications (1)

Publication Number Publication Date
DK1292303T3 true DK1292303T3 (da) 2004-09-06

Family

ID=27359046

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01911078T DK1292303T3 (da) 2000-02-17 2001-02-21 Stabil farmaceutisk formulering omfattende torsemidmodifikation II

Country Status (20)

Country Link
US (1) US6482417B2 (pl)
EP (1) EP1292303B1 (pl)
JP (1) JP2004522780A (pl)
CN (1) CN1505512A (pl)
AT (1) ATE266404T1 (pl)
CA (1) CA2410802A1 (pl)
DE (2) DE1292303T1 (pl)
DK (1) DK1292303T3 (pl)
ES (1) ES2193007T3 (pl)
HR (1) HRP20030762A2 (pl)
HU (1) HUP0600143A2 (pl)
IL (1) IL157539A0 (pl)
IS (1) IS6919A (pl)
MX (1) MXPA03007908A (pl)
NO (1) NO20033699L (pl)
PT (1) PT1292303E (pl)
SI (1) SI1292303T1 (pl)
SK (1) SK11632003A3 (pl)
TR (1) TR200401462T4 (pl)
WO (1) WO2002067935A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
WO2005044187A2 (en) * 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
CN100421662C (zh) * 2005-11-08 2008-10-01 周卓和 托拉塞米分散片及其制备方法和应用
CN100372534C (zh) * 2006-04-20 2008-03-05 南京海辰药业有限公司 托拉塞米冻干制剂及制备方法
US20080213362A1 (en) * 2007-02-02 2008-09-04 Lawrence Solomon Compositions and methods using torsemide
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
KR100405116B1 (ko) * 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
AU781461C (en) * 1999-08-11 2006-02-23 Teva Pharmaceutical Industries Ltd. Torsemide polymorphs

Also Published As

Publication number Publication date
US20020035135A1 (en) 2002-03-21
EP1292303A1 (en) 2003-03-19
DE60103276T2 (de) 2005-06-23
HRP20030762A2 (en) 2005-08-31
JP2004522780A (ja) 2004-07-29
IS6919A (is) 2003-08-20
NO20033699D0 (no) 2003-08-20
TR200401462T4 (tr) 2004-08-23
PT1292303E (pt) 2004-09-30
DE60103276D1 (de) 2004-06-17
WO2002067935A1 (en) 2002-09-06
EP1292303B1 (en) 2004-05-12
SK11632003A3 (sk) 2004-04-06
MXPA03007908A (es) 2004-12-06
US6482417B2 (en) 2002-11-19
HUP0600143A2 (en) 2006-10-28
IL157539A0 (en) 2004-03-28
EP1292303A4 (en) 2003-07-09
ATE266404T1 (de) 2004-05-15
ES2193007T1 (es) 2003-11-01
CA2410802A1 (en) 2002-09-06
SI1292303T1 (en) 2004-10-31
ES2193007T3 (es) 2004-11-01
CN1505512A (zh) 2004-06-16
DE1292303T1 (de) 2003-09-18
NO20033699L (no) 2003-10-10

Similar Documents

Publication Publication Date Title
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
PT1412384E (pt) Formulação estável de glp-1 modificado
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
HUP0101237A1 (hu) Elnyújtott kioldódású gyógyszerkészítmények
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
MY125766A (en) Flash-melt oral dosage formulation
TW200510375A (en) New compounds
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
SE9504661D0 (sv) New compounds
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
HUP0301349A2 (hu) IL-11-tartalmú készítmények
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
MY127350A (en) Flash-melt oral dose formulations
DK1007006T3 (da) Formulering af cefadroxilmonohydrattablet
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
EA200501901A1 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путём
AP2003002763A0 (en) Controlled release formulations for oral administration
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
BG106155A (en) Novel derivatives and analogues of galanthamin
DK1292303T3 (da) Stabil farmaceutisk formulering omfattende torsemidmodifikation II
SE0102440D0 (sv) New compound
CA2429639A1 (en) Stable azithromycin monohydrate
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
SE0001916D0 (sv) Novel formulation